GlaxoSmithKline (GSK) has agreed to acquire Rapt Therapeutics for $2.2 billion, the companies said today, in a deal intended to bolster the buyer’s pipeline with Rapt’s ozureprubart (RPT904), a ...

The company applies AI to optimize molecules across discovery and production with aims to contribute to the rebuilding of U.S.-based drug innovation and manufacturing.

Astellas Gene Therapies remains intent on treating X-linked Myotubular Myopathy (XLMTM) through a gene therapy—but instead of AAV-based resamirigene bilparvovec (AT132), Astellas is now partnering ...

Data from several dozen human volunteers showed that blocking sEH raised epoxy-oxylipin levels and reduced harmful immune ...

Researchers suggest that wound dressings infused with antioxidants such as catalase could be an effective future treatment.

Stopping cancer cells from entering a soft biomechanical state could help the immune system clear dormant cancer metastasis.

Sarepta Therapeutics saw its stock skid 11% after the company announced preliminary unaudited 2025 sales results that missed analyst forecasts for its marketed Elevidys® (delandistrogene ...

Scientists first read the human genome, a three-billion-letter biological book, in April 2003. Since then, researchers have steadily advanced the ability to write DNA, moving far beyond single-gene ...

UC San Diego leads a $25.8 million ARPA-H funded project to 3D bioprint patient-specific human livers, aiming to eliminate organ shortages.

Using CLASSIC, Rice researchers realized that circuits are variable, having multiple pathways to elicit the same outcome.

Researchers say the living sensor display technology may have potential applications beyond human healthcare, in veterinary ...

Formerly Somite AI, the rebranded company aims to broaden the regenerative medicine landscape by building AI models that ...